---
title: "RASi ACEI ARB"
date: "2023-07-29"
enableToc: false
tags:
  - building
alias:
  - ARB
  - ACEI
  - RASi
---

> [!info]
>
> ğŸŒ± ä¾†è‡ªï¼š[[Treatment of Chronic HF with Reduced EF]]

# RASi ACEI ARB

> Choose one of ARNI (ARB + neprilysin inhib),
> ACEI or ARB

36-hr washout when transitioning ACEI to ARNI

- ARNI preferred RASi in NYHA II-IV.
  - Neutral endopeptidase (NEP, aka neprilysin) degrades natriuretic peptides,
    - bradykinin & angiotensins.
  - Valsartan + sacubitril (NEPi) â†“ CV mort & HF hosp c/w ACEi;
    - â†‘ HoTN, AKI (NEJM 2014;371:993 & 2019;380:539).
  - Contraindicated if h/o angioedema.
  - BNP æ‡‰è©²æœƒä¸Šå‡ â†‘ ï¼Œå›  ç‚º: ARNI å«æœ‰ neprilysin inhibitorï¼Œ
    - æœƒæ¸›å°‘ BNP çš„ â†’ é™è§£ï¼Œ
    - ä½¿ç”¨ ARNI çš„ â†’ æœŸé–“ï¼Œå¯ä»¥ âœ” ç”¨ NT pro-BNP ä¾†ç›£æ¸¬ HF
- ACEI: if unable to tolerate or afford ARNI. â†“ mortality vs. placebo.
  - High-dose more effic. than low.
- Watch for
  - â†‘ Cr,
  - â†‘ K (ameliorate by low-K diet, diuretics, K binders),
  - cough,
  - angioedema.
- ARB:
  - consider if cannot tolerate
  - ACEI (eg, b/c cough) as noninferior
  -
